The University of Chicago Header Logo

Connection

James J. Dignam to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications James J. Dignam has written about Breast Neoplasms.
James J. Dignam
Connection Strength
2.627
Breast Neoplasms
  1. Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2021 04 06; 113(4):349-350.
    View in: PubMed
    Score: 0.300
  2. Some additional thoughts on time-varying treatment effects in breast cancer. J Clin Oncol. 2011 Nov 20; 29(33):4469-70; author reply 4470.
    View in: PubMed
    Score: 0.156
  3. Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer. 2009 Nov 15; 115(22):5272-83.
    View in: PubMed
    Score: 0.136
  4. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):595-602.
    View in: PubMed
    Score: 0.126
  5. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008 Aug 20; 26(24):4027-34.
    View in: PubMed
    Score: 0.125
  6. Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat. 2009 Jul; 116(1):209-10.
    View in: PubMed
    Score: 0.124
  7. The ongoing search for the sources of the breast cancer survival disparity. J Clin Oncol. 2006 Mar 20; 24(9):1326-8.
    View in: PubMed
    Score: 0.106
  8. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006 Jun; 97(3):245-54.
    View in: PubMed
    Score: 0.104
  9. Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol. 2004 Jun; 15(6):850-1.
    View in: PubMed
    Score: 0.093
  10. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003 Oct 01; 95(19):1467-76.
    View in: PubMed
    Score: 0.089
  11. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001; (30):36-43.
    View in: PubMed
    Score: 0.074
  12. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000 Mar 04; 355(9206):848-9.
    View in: PubMed
    Score: 0.070
  13. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000 Jan-Feb; 50(1):50-64.
    View in: PubMed
    Score: 0.069
  14. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials. 1998 Dec; 19(6):575-88.
    View in: PubMed
    Score: 0.064
  15. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer. 1997 Jul 01; 80(1):80-90.
    View in: PubMed
    Score: 0.058
  16. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997 Jun 04; 89(11):776-82.
    View in: PubMed
    Score: 0.058
  17. Bayesian approach for flexible modeling of semicompeting risks data. Stat Med. 2014 Dec 20; 33(29):5111-25.
    View in: PubMed
    Score: 0.048
  18. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.044
  19. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10; 30(32):3960-6.
    View in: PubMed
    Score: 0.042
  20. Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol. 2012 Jul; 19(7):2334-44.
    View in: PubMed
    Score: 0.040
  21. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16; 103(6):478-88.
    View in: PubMed
    Score: 0.037
  22. Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):257-64.
    View in: PubMed
    Score: 0.035
  23. Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group. J Natl Cancer Inst. 2010 Feb 24; 102(4):279-80; author reply 280-2.
    View in: PubMed
    Score: 0.034
  24. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010 May; 17(5):1398-405.
    View in: PubMed
    Score: 0.034
  25. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21.
    View in: PubMed
    Score: 0.034
  26. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009 May 20; 27(15):2466-73.
    View in: PubMed
    Score: 0.033
  27. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20.
    View in: PubMed
    Score: 0.029
  28. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.029
  29. A missing data approach to semi-competing risks problems. Stat Med. 2007 Feb 20; 26(4):837-56.
    View in: PubMed
    Score: 0.028
  30. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9.
    View in: PubMed
    Score: 0.026
  31. Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med. 2005 Jun; 20(6):487-96.
    View in: PubMed
    Score: 0.025
  32. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72.
    View in: PubMed
    Score: 0.024
  33. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10; 364(9437):858-68.
    View in: PubMed
    Score: 0.024
  34. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol. 2004 Jul 01; 22(13):2554-66.
    View in: PubMed
    Score: 0.023
  35. Semiparametric models for cumulative incidence functions. Biometrics. 2004 Mar; 60(1):182-90.
    View in: PubMed
    Score: 0.023
  36. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507.
    View in: PubMed
    Score: 0.023
  37. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15; 20(20):4141-9.
    View in: PubMed
    Score: 0.021
  38. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001 Aug; 28(4):400-18.
    View in: PubMed
    Score: 0.019
  39. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 02; 93(9):684-90.
    View in: PubMed
    Score: 0.019
  40. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001 Jan 17; 93(2):112-20.
    View in: PubMed
    Score: 0.018
  41. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001; (30):62-6.
    View in: PubMed
    Score: 0.018
  42. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999 Aug 01; 86(3):429-38.
    View in: PubMed
    Score: 0.017
  43. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12; 353(9169):1993-2000.
    View in: PubMed
    Score: 0.017
  44. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998 Feb; 16(2):441-52.
    View in: PubMed
    Score: 0.015
  45. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19; 89(22):1673-82.
    View in: PubMed
    Score: 0.015
  46. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 06; 88(21):1529-42.
    View in: PubMed
    Score: 0.014
  47. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul; 14(7):1982-92.
    View in: PubMed
    Score: 0.013
  48. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.013
  49. Breast cancer trials on trial: a case of conflicting ethical interests. Cancer. 1995 Oct 01; 76(7):1294-5.
    View in: PubMed
    Score: 0.013
  50. Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure. Stat Med. 2014 Nov 20; 33(26):4605-26.
    View in: PubMed
    Score: 0.012
  51. Multiple imputation methods for inference on cumulative incidence with missing cause of failure. Biom J. 2011 Nov; 53(6):974-93.
    View in: PubMed
    Score: 0.010
  52. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.